Arx analysts completed a study on strategies used by pharmaceutical organizations when engaging thought leaders during each phase of a product’s lifecycle; The white paper “Developing Lifecycle-based KOL Engagement Strategies” presents key study findings.
- 70% of surveyed companies employ lifecycle phase approaches to engage with thought leaders
- 24% of surveyed respondents reported their company begins developing relationships with KOLs before phase 1, while close to 40% wait until phase 3
- Phase 3 Shift : beginning in phase 3, organizations start interacting more prominently with KOLs closer to patient populations and begin commercially related activities
- Launch Refocus: at launch, priority reverses in a pronounced manner: medical affairs shifts to engage local thought leadership that will serve as boots on the ground for the product going to market
- Quality of scientific support and materials is by far the most important factor influencing KOL relationships
Download the White Paper here – no sign up required:
Developing Lifecycle-based Thought Leader Engagement Strategies (Arx Research)
The findings presented in this KOL Engagement Strategies White Paper are extracted from the following study:
Thought Leader Engagement Strategies and Tactics by Phase: This study is meant to reveal how pharmaceutical organizations engage with thought leaders, which types of thought leaders are targeted during the various phases of a product development, which levels of influence are most pursued and what sort of activities are conducted during these exchanges.
(four available reports – full global research, executive summary global, executive summary US, executive summary EU)
Visit: https://www.arxresearch.com/product-category/thought-leader-management/